In a development, Phase 3 clinical trial results to test the efficiency of Bharat Biotech's Coronavirus vaccine- Covaxin were released on Wednesday which demonstrated 81 percent efficacy in preventing COVID-19 in those without prior infection after the second dose.
The company revealed that, analysis from the National Institute of Virology indicates that vaccine-induced antibodies can neutralise the UK variant strains and other heterologous strains.
Today is an important milestone in vaccine discovery, for science and our fight against coronavirus. With today's results from our Phase 3 clinical trials, we have now reported data on our COVID-19 vaccine from Phase 1, 2, and 3 trials involving around 27,000 participants," Bharat Biotech Chairman and Managing Director Krishna Ella said.
The data was generated from a trial involving 25,800 participants and "showed that the vaccine candidate was well tolerated", the company said.
The trials involved 25,800 subjects, the largest ever conducted in India, in partnership with the Indian Council of Medical Research, the Hyderabad-based company said in a statement. Over concerns of Covaxin's safety and efficacy, data from the third stage of trials reveals the vaccine's success in protecting against the coronavirus.
In order to gather further data and to evaluate the efficacy of the vaccine candidate, further clinical trials will continue through to final analysis at 130 confirmed cases.
Covaxin is one of two Covid vaccines to have been cleared for emergency use approval by the government - the other is Covishield, which has a 70 per cent efficacy after the second dose.
(With agency inputs)
